February 26, 2010 – The field of cardiovascular therapy is being transformed continuously due to the emergence of new anti-platelet agents possessing unique properties. During ACC 2010, the session “Bleeding: Why Does It Matter?” will discuss these therapies from 12:30-1:30 p.m. Saturday, March 13.
Long-term combination anti-platelet therapy after coronary intervention has been recommended as a means to reduce clinical adverse events. Educational courses on this discipline are needed in order to enhance comprehension of clinical risks and benefits of these new agents, particularly in relation to bleeding.
Lunch will be served between noon and 12:30 p.m. The session is being held in room A305 of the Georgia World Congress Center, 285 Andrew Young International Blvd., NW, Atlanta.
The event is sponsored by the Cardiovascular Research Foundation and supported by an independent medical education grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals partnership. This event is not part of the official ACC Annual Scientific Session and/or the ACC’s Innovation in Intervention: i2.
To register online visit: www.bleedingcomplications.com/register.html